AT236248T - dinukleosiden method for using oligonucleotides having modified cpg - Google Patents

dinukleosiden method for using oligonucleotides having modified cpg

Info

Publication number
AT236248T
AT236248T AT97941505T AT97941505T AT236248T AT 236248 T AT236248 T AT 236248T AT 97941505 T AT97941505 T AT 97941505T AT 97941505 T AT97941505 T AT 97941505T AT 236248 T AT236248 T AT 236248T
Authority
AT
Austria
Prior art keywords
dinukleosiden
oligonucleotides
method
modified cpg
cpg
Prior art date
Application number
AT97941505T
Other languages
German (de)
Inventor
Sudhir Agrawal
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/711,568 priority Critical patent/US5856462A/en
Application filed by Hybridon Inc filed Critical Hybridon Inc
Priority to PCT/US1997/016017 priority patent/WO1998011211A2/en
Publication of AT236248T publication Critical patent/AT236248T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/311Phosphotriesters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/312Phosphonates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
AT97941505T 1996-09-10 1997-09-10 dinukleosiden method for using oligonucleotides having modified cpg AT236248T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/711,568 US5856462A (en) 1996-09-10 1996-09-10 Oligonucleotides having modified CpG dinucleosides
PCT/US1997/016017 WO1998011211A2 (en) 1996-09-10 1997-09-10 METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES

Publications (1)

Publication Number Publication Date
AT236248T true AT236248T (en) 2003-04-15

Family

ID=24858610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97941505T AT236248T (en) 1996-09-10 1997-09-10 dinukleosiden method for using oligonucleotides having modified cpg

Country Status (11)

Country Link
US (1) US5856462A (en)
EP (1) EP0928335B1 (en)
JP (1) JP5265067B2 (en)
AT (1) AT236248T (en)
AU (1) AU4339997A (en)
CA (1) CA2265917C (en)
DE (2) DE69720481D1 (en)
DK (1) DK0928335T3 (en)
ES (1) ES2190541T3 (en)
PT (1) PT928335E (en)
WO (1) WO1998011211A2 (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (en) 1993-10-22 1996-01-12 Pasteur Institut nucleotide vector containing the composition and vaccine for immunization against hepatitis.
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
JP2005504513A (en) 2001-05-09 2005-02-17 コリクサ コーポレイション Compositions and methods for prostate cancer therapy and diagnosis
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
JP2004513615A (en) 2000-06-28 2004-05-13 コリクサ コーポレイション Compositions and methods for the treatment and diagnosis of lung cancer
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
ES2374620T3 (en) 2000-06-20 2012-02-20 Corixa Corporation Mycobacterium tuberculosis MTB32A antigen with the active site inactivated and fusion proteins thereof.
JP2002514397A (en) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル グループ,インコーポレイテッド The method of Hematomodulators using CpG oligonucleotides
CN1317009A (en) * 1998-08-03 2001-10-10 东卡罗来纳大学 Low adenosine anti-sense oligonucleotide agent, composition, reagent kit and treatments
US20020042383A1 (en) * 1998-09-09 2002-04-11 Nelson S. Yew METHYLATION AND/Or CpG REMOVAL OF PLASMID VECTORS
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US5977341A (en) * 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US5981732A (en) * 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US20040171566A1 (en) * 1999-04-06 2004-09-02 Monia Brett P. Antisense modulation of p38 mitogen activated protein kinase expression
IL140054D0 (en) * 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
US6140124A (en) * 1999-04-06 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of P38 mitogen activated protein kinase expression
US6046321A (en) * 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6013788A (en) * 1999-04-09 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad3 expression
DE19935756A1 (en) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
US6476000B1 (en) * 1999-08-13 2002-11-05 Hybridon, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1496121A3 (en) * 1999-08-13 2005-02-09 Hybridon, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2291367A1 (en) * 1999-12-06 2001-06-06 Isabelle Henry Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
AU5615601A (en) 2000-02-23 2001-09-03 Smithkline Beecham Biolog Novel compounds
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
US7105495B2 (en) * 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2001090129A2 (en) 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
HU0402259A3 (en) * 2001-09-20 2010-01-28 Glaxo Group Ltd Vaccines
ES2298269T3 (en) * 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide Analogs by Positional chemical changes.
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
ES2487645T3 (en) * 2001-06-21 2014-08-22 Dynavax Technologies Corporation chimeric immunomodulatory compounds and methods of use thereof
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
JP4319908B2 (en) 2001-08-24 2009-08-26 ジョンズホプキンスユニバーシティ Using for the treatment of pro Aero lysine and prostate cancer comprises a protease activation sequence
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
DK1456380T3 (en) * 2001-11-02 2012-07-30 Giuliani Int Ltd Smad7-inhibitors for the treatment of CNS disorders
ES2405405T3 (en) 2001-12-17 2013-05-31 Corixa Corporation Compositions and methods for therapy and diagnosis of inflammatory bowel disease
JP2005526497A (en) * 2002-02-04 2005-09-08 ビオミラ,インコーポレーテッド Immunostimulatory, covalent lipid oligonucleotide
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2004012669A2 (en) 2002-08-01 2004-02-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc Immunostimulatory Nucleic Acids
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
KR101110889B1 (en) 2003-01-06 2012-02-20 코릭사 코포레이션 Certain aminoalkyl glucosaminide phosphate compounds and their use
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotides (odn) antisense Smad7 and uses thereof in medical field
KR101107818B1 (en) * 2003-10-30 2012-01-31 콜레이 파마시티컬 그룹, 인코포레이티드 C-class oligonucleotide analogs with enhanced immunostimulatory potency
AU2005247341B2 (en) 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
JP2008534594A (en) 2005-03-31 2008-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine against Chlamydia infection
PT1877426E (en) 2005-04-29 2012-05-02 Glaxosmithkline Biolog Sa Method for preventing or treating m tuberculosis infection
KR101365538B1 (en) 2005-06-14 2014-02-21 프로톡스 테라페유틱 인코포레이티드 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
PE01462009A1 (en) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa immunogenic composition against influenza virus
EP2136836B8 (en) 2007-04-04 2017-04-12 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
EA026990B1 (en) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Antibodies which bind to human cell dec-205
SG188813A1 (en) 2007-12-24 2013-04-30 Id Biomedical Corp Quebec Recombinant rsv antigens
WO2009143292A2 (en) 2008-05-21 2009-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating pneumoconiosis with oligodeoxynucleotides
WO2010063865A1 (en) 2008-12-03 2010-06-10 Proyecto De Biomedicina Cima, S.L. Use of phenol-soluble modulins for vaccine development
KR20120093811A (en) 2009-06-24 2012-08-23 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccine
KR101696002B1 (en) 2009-06-24 2017-01-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Recombinant rsv antigens
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
BR112013011420A2 (en) 2010-11-08 2016-08-02 Infectious Disease Res Inst poliptídeos vaccines comprising non-specific nucleoside hydrolase and sterol 24-C-methyl transferase (SMT) for the treatment and diagnosis of leishmaniasis
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
BR112015024860A2 (en) 2013-03-28 2017-10-10 Infectious Disease Res Institute vaccines comprising polypeptides of Leishmania for the treatment and diagnosis of leishmaniasis
EP3492097A1 (en) 2013-08-05 2019-06-05 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
EP2952893A1 (en) 2014-06-04 2015-12-09 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Method for detecting antibody-secreting B cells specific for HLA
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc Disease vaccines hands, feet and mouth and methods of manufacture and use
KR20170099963A (en) 2014-12-19 2017-09-01 레제네상스 비.브이. Antibodies that bind human c6 and uses thereof
WO2016140702A1 (en) 2015-03-03 2016-09-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces Display platform from bacterial spore coat proteins
EP3268037A2 (en) 2015-03-09 2018-01-17 Celldex Therapeutics, Inc. Cd27 agonists
US20180066053A1 (en) 2016-04-18 2018-03-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
KR20190009308A (en) 2016-05-21 2019-01-28 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Compositions and methods for treating secondary tuberculosis and non-tuberculous mycobacterial infections
CA3036218A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
WO2018232257A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
WO2019090238A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
DE4200433A1 (en) * 1992-01-10 1993-07-15 Otto Hofstetter A process for the preparation of stable liquid with a high solids content parfuemrohstoffmischungen
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
NZ267797A (en) * 1993-05-17 1997-09-22 Univ California Retroviral vector comprising a ribozyme capable of cleaving a hiv nucleic acid capable
JPH09505465A (en) * 1993-09-28 1997-06-03 ザ ジェネラル ホスピタル コーポレイション Adjust the nerve growth, the use of antisense oligonucleotides for reversing the β / A4 amyloid-induced form
ES2267100T5 (en) * 1994-07-15 2011-04-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides.
CA2208528A1 (en) * 1994-12-22 1996-06-27 Hybridon, Inc. Synthesis of stereospecific oligonucleotide phosphorothioates

Also Published As

Publication number Publication date
US5856462A (en) 1999-01-05
WO1998011211A2 (en) 1998-03-19
AU4339997A (en) 1998-04-02
WO1998011211A3 (en) 1998-04-16
CA2265917A1 (en) 1998-03-19
ES2190541T3 (en) 2003-08-01
DK928335T3 (en)
JP2001500511A (en) 2001-01-16
PT928335E (en) 2003-07-31
EP0928335B1 (en) 2003-04-02
DK0928335T3 (en) 2003-06-16
JP5265067B2 (en) 2013-08-14
EP0928335A2 (en) 1999-07-14
DE69720481D1 (en) 2003-05-08
CA2265917C (en) 2008-07-08
DE69720481T2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
DE69128980T2 (en) Method for optimizing Rechnerkode
DE69934967D1 (en) A method for reducing the immunogenicity of proteins
DE69733594D1 (en) A process for spray-drying
DE69801517T2 (en) A method for preventing the calcification of aldehyde-fixed bioprothesenmaterialien
DE69728841D1 (en) A method for transmitting address data
DE69530277D1 (en) A method of selecting transmission features
AT203230T (en) alcohols method for preparing higher oxo-
DE69807238T2 (en) A process for remediation
DE69817181D1 (en) Method and apparatus for blindseparierung signals
DE69825878D1 (en) A method for channel allocation
DE69633312D1 (en) Method for improving the wear resistance of biocompatible polymeric components
DE69931475D1 (en) A method for treating liquids
AT188058T (en) Methods for detection of traffic-data
DE69731971D1 (en) A method for improving the stimulation treatment
DE69608152T2 (en) Method and system for recycling carpets
DE69816789D1 (en) Method and system for gesture-controlled option selection
DE69427826D1 (en) Method and system for cleaning boreholes
DE69618337T2 (en) A method for driving stability increase
AT246361T (en) A process for the determination of IgE
AT328114T (en) length polymorphisms method for determining DNA
DE69738854D1 (en) A process for korneallaserchirurgie
DE69503623D1 (en) Improved method for catheter segment-fixing
DE69619247T2 (en) A method for sequencing nucleic acids
DE69734263D1 (en) A method for isolating ribonucleic acids.
DE59913529D1 (en) A method for post-crosslinking of hydrogel with n-acyl-2-oxazoli-dinonen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0928335

Country of ref document: EP

REN Ceased due to non-payment of the annual fee